Literature DB >> 14680320

Natural history, management, and surveillance of recurrent squamous cell penile carcinoma: a risk-based approach.

Ricardo F Sánchez-Ortiz1, Curtis A Pettaway.   

Abstract

For men with penile carcinoma, surveillance strategies may be tailored to the risks of local and regional recurrence, which vary according to the pathologic characteristics of the primary tumor and the modalities employed for local therapy (phallus sparing or extirpative) and regional therapy (surveillance or lymphadenectomy). Men at a higher risk for local or regional recurrence who should have more rigorous follow-up include those (1) treated with phallus-sparing strategies such as laser ablation, topical therapies, or radiotherapy; (2) patients with clinically negative inguinal lymph nodes who are managed without lymphadenectomy despite high-risk primary tumors (pT2-3, grade 3, vascular invasion); and (3) those with lymph node metastases after lymphadenectomy. Good candidates for less-stringent surveillance include patients with low-risk primary tumors (pTis, pTa, pT1, grades 1-2) and those with negative inguinal nodes after lymphadenectomy whose primary tumors were managed with partial or total penectomy.

Entities:  

Mesh:

Year:  2003        PMID: 14680320     DOI: 10.1016/s0094-0143(03)00055-7

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  3 in total

Review 1.  [Penile cancer--aftercare with results. How much is necessary?].

Authors:  R Paul; H van Randenborgh; S Schöler; F May; R Hartung
Journal:  Urologe A       Date:  2005-09       Impact factor: 0.639

Review 2.  Surveillance strategies in the management of penile cancer.

Authors:  Simpa S Salami; Jeffrey S Montgomery
Journal:  Transl Androl Urol       Date:  2017-10

3.  Intraarterial chemotherapy with gemcitabine and cisplatin in locally advanced or recurrent penile squamous cell carcinoma.

Authors:  Jian-Ye Liu; Yong-Hong Li; Zhuo-Wei Liu; Zhi-Ling Zhang; Yun-Lin Ye; Kai Yao; Hui Han; Zi-Ke Qin; Fang-Jian Zhou
Journal:  Chin J Cancer       Date:  2013-05-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.